AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02075216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myoblast Transplantation
Description: For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
Study NCT03551509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ArthroFLEX ECM scaffold graft
Description: In patients receiving a graft, thru mini open technique the lateral portal incision will be extended vertically approximately 5-6 cm. A standard, deltoid-splitting, mini-open approach will then be performed, leaving the deltoid attachment to the acromion intact. For arthroscopic technique same method of fixation will be used below. The dermis graft will be sized and cut so as to cover the entire repair site in both medial-lateral and anterior-posterior dimensions.
Study NCT03551509 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.
Study NCT03551509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.
Study NCT03551509 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Crossover
Description: Patients randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
Study NCT04373239 — intervention group
Intervention type: PROCEDURE
Intervention: Assisted Reproductive Technology
Description: Assisted reproductive technology includes IVF and IVF+ICSI.
Study NCT02119611 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Deep Brain Stimulation management
Description: The DBS surgery will be performed according to standard of care in the centers of referral. If performed at the NIH, this will be done under protocol 11-N-0211 or other protocols permitting DBS surgery depending on future availability.
Study NCT02075216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neonatal Cystourethroscope Injection
Description: 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
Study NCT01155440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1% Lidocaine 1mg/kg/hr IV drip x 48hr
Study NCT02975934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered daily.
Study NCT02975934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate or Enzalutamide or Docetaxel
Description: Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
Study NCT02724631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TubeClear® intervention
Description: The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
Study NCT03644186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy plus HER2 Blockade
Study NCT03644186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Chemotherapy plus HER2 Blockade
Study NCT03644186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Chemotherapy plus HER2 Blockade
Study NCT03644186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Study NCT03644186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Study NCT01155440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural block
Description: 0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
Study NCT02818946 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: Detection of cancer by MRI for pathologic nipple discharge
Study NCT01193374 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician enhanced screening and counseling prompts
Description: PDA based health risk screening for well child issues and obesity risks
Study NCT01193374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician enhanced screening and counseling prompts
Description: PDA based health risk screening for well child issues and obesity risks
Study NCT01193374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored education and motivational materials
Description: Specific tailoring for those interested in change vs not . Two newsletters over 3 mpn.
Study NCT01193374 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: basic educational brochure
Description: Booklet by ADA sent x 1.
Study NCT00955409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001(3µg) + QS21
Description: Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
Study NCT03644186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Study NCT03644186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Study NCT00776984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 5mcg/day
Description: Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
Study NCT04050683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Description: Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). Subjects with abnormal heart pressures during TIPS will have a right heart catheterization (RHC) to monitor heart function, blood flow, and pressures in and around the heart. The subject will be admitted to the Cardiovascular Intensive Care Unit and have a TTE all of which are standard of care. Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; TTEs; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. Diagnostic RHC will be done as needed per standard of care.
Study NCT04050683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Description: Subject's with normal heart pressures who are having elective (planned in advance and not due to an emergency) TIPS due to refractory ascites (fluid build up in the belly that does not go away or comes back shortly after being removed). Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). The subject will be admitted to the hospital after TIPS for standard of care monitoring.~Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes.
Study NCT01572506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biotin RBC survival
Study NCT02638948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142
Description: BMS986142 specific dose on specific days
Study NCT02638948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of BMS-986142 specific dose on specific days
Study NCT02638948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate specific dose on specific days
Study NCT02638948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate specific dose on specific days
Study NCT02901015 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment battery A
Description: Social cognition tests version A are administered to the patients
Study NCT02901015 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment battery B
Description: Social cognition tests version B are administered to the patients
Study NCT03863340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interruptions of work tasks
Description: During each activity two interruptions/breaks were selected randomly from a set of ten predetermined actions:~Active break types:~* Move shoulder and upper back~* Swing arms near the body~* Three slow but forceful elevations of the shoulders, a relaxation exercise based on the principles developed by Jacobson~* Stand up and stretch~* Slowly turn head in all possible directions.~Passive break types:~* Tell a couple of jokes~* Stand up and have a drink~* Relaxing the trapezius~* Questions on actual posture and feelings of comfort / discomfort.~* A short rest on the couch
Study NCT00797654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information-motivation-behavior skills and cognitive processing therapy
Description: Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
Study NCT00797654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre and Post HIV-Test Counseling
Description: Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
Study NCT00797654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre and Post HIV-Test Counseling
Description: Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
Study NCT03265600 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training for Primary Care
Description: MTPC is a referral-based, insurance-reimbursable 8-week program that can be delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours long for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action planning protocol during Week 7.
Study NCT03265600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 60-minute Introduction to Mindfulness
Description: Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, discussion, and an orientation to an 8-week mindfulness group. They are also given a list of leading community, online, print, and smartphone mindfulness resources.
Study NCT04822038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 5000 UI Vitamin D3 daily by 4 weeks
Study NCT04822038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary recommendations
Description: Dietary recommendations based on food rich in 25 (OH) vitamin D
Study NCT00036569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00036569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa
Description: 0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
Study NCT03276351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-Stemmed with Hybrid Fixation
Description: Long-stemmed revision implant with hybrid fixation for total knee arthroplasty
Study NCT03276351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short-Stemmed with Augmented Fixation
Description: Short-stemmed primary implant with augmented fixation for total knee arthroplasty
Study NCT04984148 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: Contrast-enhanced thoracic computed tomography
Study NCT04936152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mime therapy using tablet PC mirror application
Description: After the baseline assessment, The patient in the experimental group will receive mirror therapy and mime therapy.~Exercises time period is 30 min/session~Mime Therapy Using Tablet PC:~Mirror therapy using tablet PC mirror application We will use a tablet PC mirror application that can convert images from right to left. In the mirror group, the mirror application was used during the exercise. Patients watched the tablet PC screen. The mirror application converts the image from right to left.~• Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present.
Study NCT04936152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the control intervention including the mime therapy
Description: After the baseline assessment, The patient in the experimental group will receive mime therapy Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present.
Study NCT00840853 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19CAR/virus specific T cells
Description: CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.
Study NCT00840853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl and Tylenol
Description: Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
Study NCT01087892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic drink containing the live strain
Description: Probiotic drink contains no strain
Study NCT01087892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo probiotic
Description: Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
Study NCT01734304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination for postremission therapy in AML
Description: Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
Study NCT03536806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. BP will be measured before injection.
Study NCT03536806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canrenone
Description: Patients assigned to canrenone group will be administered canrenone in bolus of 200 mg diluted to 10 cm3 within 2-3 minutes in one dose. Drug administration will be stopped in case of serious adverse event. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
Study NCT02471196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: ORM-12741 low dose twice a day
Study NCT02471196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: ORM-12741 high dose twice a day
Study NCT02471196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day
Study NCT02846974 — intervention group
Intervention type: DEVICE
Intervention: Pulse oximeter
Description: A pulse oximeter will be used for calibration
Study NCT03273634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Pill
Description: once daily at night time
Study NCT03273634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01511848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFP (ferriprox) and deferasirox (ICL 670)
Description: Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).~Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.~Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.~Other Name: ICL670
Study NCT01511848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFP, DFO
Description: Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days
Study NCT04395105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose Dexamethasone
Description: IV Dexamethasone administered once daily: 16 mg from day 1 to 5 and 8 mg from day 6 to 10
Study NCT00862134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR104
Description: 770 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00862134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00862134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 60 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00862134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Description: Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02560948 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: 4 x 2 injections over 21 days
Study NCT02560948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: 4 x 2 injections over 21 days
Study NCT00737165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal suicide prevention program
Description: A community intervention of multimodal suicide prevention program includes following components:~1. Building support networks for suicide prevention and mental health promotion in public health system~2. Primary prevention of suicide and suicide related behaviors~3. Secondary prevention of suicide and suicide related behaviors~4. Tertiary prevention; after care for suicide survivors~5. Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders~6. Suicide prevention targeting for people with work-related problems
Study NCT00737165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Suicide prevention program as usual
Description: Usual suicide prevention program
Study NCT00955409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001(10µg) + QS21
Description: Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
Study NCT00955409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001(30µg) + QS21
Description: Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
Study NCT01690858 — intervention group
Intervention type: OTHER
Intervention: blood sample
Description: blood sampling at inclusion and throughout pregnancy when pregnant
Study NCT01011829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
Study NCT01011829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).